Molecular Genetics and Metabolism Reports最新文献

{"title":"Familial schwannomatosis carrying LZTR1 variant p.R340X with brain tumor: A case report","authors":"Masaki Ibe ,&nbsp;Shinobu Tamura ,&nbsp;Hideki Kosako ,&nbsp;Yusuke Yamashita ,&nbsp;Masamichi Ishii ,&nbsp;Masaoh Tanaka ,&nbsp;Hiroyuki Mishima ,&nbsp;Akira Kinoshita ,&nbsp;Sadahiro Iwabuchi ,&nbsp;Shuhei Morita ,&nbsp;Ko-ichiro Yoshiura ,&nbsp;Shinichi Hashimoto ,&nbsp;Naoyuki Nakao ,&nbsp;Shigeaki Inoue","doi":"10.1016/j.ymgmr.2024.101107","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101107","url":null,"abstract":"<div><p>Schwannomatosis (SWN) is a rare genetic condition characterized by the risk of developing multiple benign peripheral nerve sheath tumors; however, the risk of developing malignant tumors in patients with SWN remains unclear. This study described the case of a 57-year-old Japanese man diagnosed with SWN whose older brother also had SWN. Whole-exome sequencing identified a heterozygous mutation [c.1018C &gt; T (p.Arg340X)] in the <em>LZTR1</em> gene, linked to the RAS/MAPK pathway, in the patient and his brother. Moreover, the patient had aphasia and right-sided paralysis because of a brain tumor. RNA sequencing revealed the remarkable upregulation of several genes associated with oxidative stress, such as the reactive oxygen species pathway and oxidative phosphorylation, a downstream effector of the RAS/MAPK pathway, in the the patient and his brother compared with healthy volunteers. The final diagnosis was <em>LZTR1</em>-related familial SWN, and the dysregulated RAS/MAPK pathway in this patient might be associated with brain tumorigenesis.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000600/pdfft?md5=f82983422b5d7b997e3c651235e5fb37&pid=1-s2.0-S2214426924000600-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141423750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term use of investigational β-Hydroxybutyrate salts in children with multiple acyl-CoA dehydrogenase or pyruvate dehydrogenase deficiency","authors":"Andrew A.M. Morris ,&nbsp;Bernard Cuenoud ,&nbsp;Philippe Delerive ,&nbsp;Helen Mundy ,&nbsp;Bernd C. Schwahn","doi":"10.1016/j.ymgmr.2024.101104","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101104","url":null,"abstract":"<div><p>Several disorders of energy metabolism have been treated with exogenous ketone bodies. The benefit of this treatment is best documented in multiple acyl-CoA dehydrogenase deficiency (MADD) (MIM#<span>231680</span><svg><path></path></svg>). One might also expect ketone bodies to help in other disorders with impaired ketogenesis or in conditions that profit from a ketogenic diet. Here, we report the use of a novel preparation of dextro-β-hydroxybutyrate (D-βHB) salts in two cases of MADD and one case of pyruvate dehydrogenase (PDH) deficiency (MIM#<span>312170</span><svg><path></path></svg>). The two patients with MADD had previously been on a racemic mixture of D- and L‑sodium hydroxybutyrate. Patient #1 found D-βHB more palatable, and the change in formulation corrected hypernatraemia in patient #2. The patient with PDH deficiency was on a ketogenic diet but had not previously been given hydroxybutyrate. In this case, the addition of D-βHB improved ketosis. We conclude that NHS101 is a good candidate for further clinical studies in this group of diseases of inborn errors of metabolism.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000570/pdfft?md5=3e0c53b41aae64a8fc4f1efb683842e9&pid=1-s2.0-S2214426924000570-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141424472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tocilizumab effectively reduces flares of hyperimmunoglobulin D syndrome in children: Three cases in China","authors":"Chenxi Li ,&nbsp;Xiangyuan Chen ,&nbsp;Xilong Tang ,&nbsp;Huasong Zeng ,&nbsp;Juan Zhou","doi":"10.1016/j.ymgmr.2024.101105","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101105","url":null,"abstract":"<div><p>Hyperimmunoglobulin D syndrome (HIDS) is a rare but severe autoinflammatory disease with a poor prognosis if not diagnosed and treated early. Here, we report three cases of HIDS in children with typical clinical manifestations and a clear genetic diagnosis. Patient 1 experienced recurrent fever flares with a maculo-papular skin rash. Patient 2 presented with periodic fever, cholestasis, lymphadenopathy, aphthous stomatitis, arthralgia, and abdominal pain and underwent surgery for intestinal obstruction. Patient 3, a sibling of patient 2, presented with periodic fever and underwent a surgical procedure for intussusception. All three patients were administered interleukin (IL)-6 receptor antagonist (tocilizumab). The results showed that tocilizumab effectively reduced inflammatory flares. Early diagnosis and tocilizumab treatment are effective at improving the prognosis of HIDS patients.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000582/pdfft?md5=19f62876f2e56f6c493db06a1c7380a0&pid=1-s2.0-S2214426924000582-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141424471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histologic and ultrastructural study of intracranial Gaucheroma causing deafness in a patient with Gaucher disease type 3: Effects of substrate reduction therapy","authors":"Shoji Yano ,&nbsp;Rachel McGowan ,&nbsp;Mikako Warren","doi":"10.1016/j.ymgmr.2024.101106","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101106","url":null,"abstract":"<div><p>Hearing loss is frequently associated with Gaucher disease (GD). Gaucher cells are enlarged reticuloendothelial cells containing glucocerebroside in the lysosomes due to deficiency of the glucocerebrosidase. Gaucheromas consist of accumulated Gaucher cells. Gaucher cells accumulate in variable tissues including the liver, spleen, bone marrow, and the middle ear and the mastoid causing conductive hearing loss. Neurons and astrocytes in the central nervous system are affected in neuronopathic GD leading to sensorineural hearing loss. Gaucheromas can develop even in patients treated with enzyme replacement therapy (ERT). We report a 19-year-old female patient with GD type 3 who developed profound bilateral hearing loss associated with intracranial Gaucheroma. Combination therapy of ERT with imiglucerase and substrate reduction therapy (SRT) with eliglustat significantly decreased the size of Gaucher cells and cleared the characteristic microtubular structures in the lysosomes in Gaucher cells. Early implementation of SRT may prevent at least conductive hearing impairment in GD although it may not prevent sensorineural hearing loss due to inner hair cell dysfunction which is also known to be associated with neuronopathic GD.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000594/pdfft?md5=8ca89347a9625bde9b1ee36d251bf75e&pid=1-s2.0-S2214426924000594-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141323237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between circulating phenylalanine and the temporal risk of impaired insulin markers in gestational diabetes mellitus","authors":"Hao Wu ,&nbsp;Qiong Wang ,&nbsp;Yanmin Chen ,&nbsp;Danqing Chen","doi":"10.1016/j.ymgmr.2024.101090","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101090","url":null,"abstract":"<div><h3>Background</h3><p>We aimed to contrast plasma amino acid concentrations in pregnant women with Gestational Diabetes Mellitus (GDM) to those without, to analyze the link between plasma amino acid concentrations, GDM, insulin resistance, and insulin secretion at 24–28 weeks of gestation.</p></div><div><h3>Methods</h3><p>The research employed a retrospective case-control study design at a single center. Basic demographic and laboratory data were procured from the hospital's case system. The study encompassed seventy women without gestational diabetes mellitus (GDM) and thirty-five women with GDM matched in a 1-to-2 ratio for age and pre-pregnancy BMI. Utilizing high-performance liquid chromatography-mass spectrometry (HPLC-MS), peripheral fasting plasma amino acid concentrations in these women, during mid-pregnancy, were duly measured. We carefully evaluated the significant differences in the quantitative data between the two groups and developed linear regression models to assess the independent risk factors affecting insulin resistance and insulin secretion.</p></div><div><h3>Results</h3><p>Significant variations in insulin secretion and resistance levels distinguished GDM Group from the non-GDM group at three distinct time points, alongside relatively elevated serum Glycosylated Hemoglobin (HbA1c) levels. Triglycerides (TG) were also significantly increased in those with GDM during adipocytokine observations. Apart from glutamic acid and glutamine, the concentrations of the remaining 16 amino acids were notably increased in GDM patients, including all branched chain amino acids(BCAAs) and aromatic amino acids(AAAs). Ultimately, it was ascertained that fasting serum phenylalanine levels were independent risk factors affecting insulin resistance index and insulin secretion at various phases.</p></div><div><h3>Conclusions</h3><p>Various fasting serum amino acid levels are markedly increased in patients with GDM, specifically phenylalanine, which may play role in insulin resistance and secretion.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000430/pdfft?md5=4cf9842462b86f0a63e8f8761bb8f90a&pid=1-s2.0-S2214426924000430-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141323236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The challenge of adults with phenylketonuria who have been lost to care; a single center's attempt to reach those diagnosed with PKU over 60 years of newborn screening","authors":"S. Sacharow ,&nbsp;E. Zhu ,&nbsp;S. Hollander","doi":"10.1016/j.ymgmr.2024.101099","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101099","url":null,"abstract":"<div><h3>Background</h3><p>Those diagnosed with PKU in the early years of newborn screening (NBS) were often discharged from clinic in childhood. Long-term lost to clinic patients may be impacted by untreated PKU and uninformed about current recommendations. We aimed to contact adults away from clinic for 5–50+ years, share current recommendations, offer clinical care, and elicit factors underlying not returning to clinic.</p></div><div><h3>Methods</h3><p>Former patients were identified and offered a virtual meeting with a physician and dietitian for structured interview and education about current guidelines and treatments.</p></div><div><h3>Results</h3><p>We identified 53 eligible patients who had PKU and had not returned to clinic in ≥5 years. Of those 53, 27 were successfully contacted, 16 completed the educational intervention, and 5/16 returned to clinic. Reasons for having been away from clinic included discharge from clinic in childhood and inadequate insurance coverage. Experiences varied and some denied negative impacts after diet discontinuation. Individuals expressed a desire for convenient treatments that aligned with overall health goals. Most participants who completed the educational intervention expressed interest in returning to clinic; however, most did not return within the timeframe of the project. All 27 individuals successfully contacted agreed to be re-contacted with future updates or research opportunities.</p></div><div><h3>Discussion</h3><p>We successfully contacted half of individuals identified as having been lost to clinic follow-up long-term. Limitations included inability to make initial contact, and unwillingness to re-engage by some we reached. Those who agreed to participation desired ongoing PKU clinic and community connection. This experience will inform our process to engage current patients and re-engage those currently lost to care.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000521/pdfft?md5=f5ba2280bd37bc64912d28f82e4da7aa&pid=1-s2.0-S2214426924000521-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141290050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline variant analysis from a cohort of patients with severe hypertriglyceridemia in Brazil","authors":"Camila Mendes,&nbsp;Thereza Loureiro,&nbsp;Darine Villela,&nbsp;Marcelo Imbroinise Bittencourt,&nbsp;Joselito Sobreira,&nbsp;Diana Bermeo,&nbsp;Mireille Gomes,&nbsp;Dayse Alencar,&nbsp;Luciana Santos Serrao de Castro,&nbsp;Rodrigo Ambrosio Fock,&nbsp;Maria Luisa Tinoco,&nbsp;Henrique Galvão,&nbsp;Cristovam Scapulatempo-Neto,&nbsp;Katia Schiavetti,&nbsp;Andreza A. Senerchia,&nbsp;Maria Helane Costa Gurgel","doi":"10.1016/j.ymgmr.2024.101100","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101100","url":null,"abstract":"<div><p>Hypertriglyceridemia (HTG) is a common dyslipidemia associated with an increased risk of cardiovascular disease and pancreatitis. It is well stablished that the severe cases of disease often present with an underlying genetic cause. In this study, we determined the frequency and variation spectrum of genes involved in the triglyceride metabolism in a series of Brazilian patients with severe HTG. A total of 212 patients with very high HTG, defined with fasting triglycerides (TG) ≥ 880 mg/ dL, that underwent a multi-gene panel testing were included in this research. Germline deleterious variants (i.e. Pathogenic/Likely Pathogenic (P/LP) variants) were identified in 28 out of 212 patients, reflecting an overall diagnostic yield of 13% in our cohort. Variants of unknown significance (VUS) were identified in 87 patients, and represent 80% of detected variants in this dataset. We confirm the <em>LPL</em> as the most frequently mutated gene in patients with severe HTG, and we had only one suspected case of familial chylomicronemia syndrome, caused by a homozygous variant in <em>LMF1,</em> in our cohort. Notably, we report 16 distinct and novel variants (P/LP and VUS), each of them representing a single case, not previously reported in any public databases or other studies. Our data expand our knowledge of genetic variation spectrum in patients with severe HTG in the Brazilian population, often underrepresented in public genomic databases, being also a valuable clinical resource for genetic counseling and healthcare programs in the country.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000533/pdfft?md5=53a1cef1d557a37b13de6354c762e282&pid=1-s2.0-S2214426924000533-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141286013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating prevalence of classical homocystinuria in the United States using Optum's de-identified market clarity data","authors":"Mahim Jain ,&nbsp;Mehul Shah ,&nbsp;Kamlesh M. Thakker ,&nbsp;Andrew Rava ,&nbsp;Agness Pelts Block ,&nbsp;Colette Ndiba-Markey ,&nbsp;Lionel Pinto","doi":"10.1016/j.ymgmr.2024.101101","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101101","url":null,"abstract":"<div><h3>Background and objectives</h3><p>Prevalence estimates for classical homocystinuria (HCU) are variable and likely underestimated due to underdiagnosis. Claims data represent a strong but seldom used resource to analyze prevalence of HCU. The aim of this study was to estimate a prevalence range of HCU in the US utilizing a combination of diagnosis codes, total homocysteine levels, and clinical presentations indicative of HCU.</p></div><div><h3>Methods</h3><p>This was a non-interventional retrospective cohort study, using Optum's de-identified Market Clarity Data, with a patient identification period from January 01, 2016, through September 30, 2021. An algorithm was developed to identify 2 cohorts of patients using broad and strict definitions of HCU. The index date was the date within the identification period on which the first criterion was met for the inclusion criteria. Baseline demographics, clinical characteristics, and complications were assessed and summarized using descriptive statistics. Crude and standardized prevalence estimates were calculated.</p></div><div><h3>Results</h3><p>There were 3880 and 633 patients that met the relevant inclusion criteria for the broad and strict cohorts, respectively. The projected US prevalence of HCU was calculated to be 17,631 and 3466 based on the broad and strict definitions, respectively. The average annual standardized prevalence across 2016–2020 was 5.29 and 1.04 per 100,000 people for the broad and strict cohorts, respectively.</p></div><div><h3>Conclusions</h3><p>Prevalence estimates of HCU vary depending on databases or datasets used and identification criteria. Many patients with clinical presentations suggesting a diagnosis of HCU did not have an associated diagnosis, potentially indicating underdiagnosis or underreporting. Future research should study alternative methods, such as the identification algorithm in our analysis, to better diagnose and understand the true prevalence of HCU.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000545/pdfft?md5=afd6ff7043d40b029120d028aaa267e0&pid=1-s2.0-S2214426924000545-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141290049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fabry disease caused by the GLA p.Gly183Asp (p.G183D) variant: Clinical profile of a serious phenotype","authors":"Zhiquan Liu ,&nbsp;Qi Wang ,&nbsp;Dongmei Yang ,&nbsp;Kui Mao ,&nbsp;Guohong Wu ,&nbsp;Xueping Wei ,&nbsp;Hao Su ,&nbsp;Kangyu Chen ,&nbsp;Huangshan Cardiovascular Disease Collaborative Group (HCDCG)","doi":"10.1016/j.ymgmr.2024.101102","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101102","url":null,"abstract":"<div><h3>Background</h3><p>The detailed clinical phenotype of patients carrying the α-galactosidase gene (<em>GLA</em>) <em>c.548 G</em> <em>&gt;</em> <em>A</em>/<em>p.Gly183Asp</em> (<em>p.G183D</em>) variant in Fabry disease (FD) has not been thoroughly documented in the existing literature.</p></div><div><h3>Methods</h3><p>This paper offers a meticulous overview of the clinical phenotype and relevant auxiliary examination results of nine confirmed FD patients with the <em>p.G183D</em> gene variant from two families. Pedigree analysis was conducted on two male patients with the gene variant, followed by biochemical and genetic screening of all high-risk relatives. Subsequently, evaluation of multiple organ systems and comprehensive instrument assessment were performed on heterozygotes of the <em>p.G183D</em> gene variant.</p></div><div><h3>Results</h3><p>The study revealed that all patients exhibited varying degrees of cardiac involvement, with two demonstrating left ventricular wall thickness exceeding 15 mm on echocardiography, and the remaining six exceeding 11 mm. Impaired renal function was evident in all six patients with available blood test data, two of whom underwent kidney transplantation. Eight cases reported neuropathic pain, and five experienced varying degrees of stroke or transient ischemic attack (TIA).</p></div><div><h3>Conclusion</h3><p>This study indicates that the <em>GLA p.G183D</em> gene variant can induce premature organ damage, particularly affecting the heart, kidneys, and nervous system.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000557/pdfft?md5=e055c350b58c598ee3027ff624a0295b&pid=1-s2.0-S2214426924000557-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141243032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Citrin-deficient patient-derived induced pluripotent stem cells as a pathological liver model for congenital urea cycle disorders","authors":"Mai Okano ,&nbsp;Masahiro Yasuda ,&nbsp;Yui Shimomura ,&nbsp;Yoshikazu Matsuoka ,&nbsp;Yasumasa Shirouzu ,&nbsp;Tatsuya Fujioka ,&nbsp;Masatoshi Kyo ,&nbsp;Shoji Tsuji ,&nbsp;Kazunari Kaneko ,&nbsp;Hirofumi Hitomi","doi":"10.1016/j.ymgmr.2024.101096","DOIUrl":"https://doi.org/10.1016/j.ymgmr.2024.101096","url":null,"abstract":"<div><p>Citrin deficiency is a congenital secondary urea cycle disorder lacking useful disease models for effective treatment development. In this study, human induced pluripotent stem cells (iPSCs) were generated from two patients with citrin deficiency and differentiated into hepatocyte-like cells (HLCs). Citrin-deficient HLCs produced albumin and liver-specific markers but completely lacked citrin protein and expressed argininosuccinate synthase only weakly. In addition, ammonia concentrations in a medium cultured with citrin-deficient HLCs were higher than with control HLCs. Sodium pyruvate administration significantly reduced ammonia concentrations in the medium of citrin-deficient HLCs and slightly reduced ammonia in HLCs differentiated from control iPSCs, though this change was not significant. Our results suggest that sodium pyruvate may be an efficient treatment for patients with citrin deficiency. Citrin-deficient iPSCs are a pathological liver model for congenital urea cycle disorders to clarify pathogenesis and develop novel therapies.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000491/pdfft?md5=b5aa71b1246a8266b4bb51e12b4128c4&pid=1-s2.0-S2214426924000491-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141241588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}